Reviews on covid drug development
(Die Seite wurde neu angelegt: „{{tp|p=32226821|t=2020. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases |pdf=|usr=}} {{tp|p=322…“) |
|||
Zeile 35: | Zeile 35: | ||
{{tp|p=32311668|t=ä. SARS-Cov-2 infection: response of human immune system and possible implications for the rapid test and treatment |pdf=|usr=}} | {{tp|p=32311668|t=ä. SARS-Cov-2 infection: response of human immune system and possible implications for the rapid test and treatment |pdf=|usr=}} | ||
{{tp|p=32278811|t=ä. Drug repositioning is an alternative for the treatment of coronavirus COVID-19 |pdf=|usr=}} | {{tp|p=32278811|t=ä. Drug repositioning is an alternative for the treatment of coronavirus COVID-19 |pdf=|usr=}} | ||
− | + | {{tp|p=32272396|t=ä. The Possible of Immunotherapy for COVID-19: a Systematic Review |pdf=|usr=}} | |
{{tp|p=32251732|t=ä. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage |pdf=|usr=}} | {{tp|p=32251732|t=ä. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage |pdf=|usr=}} | ||
{{tp|p=32305589|t=ä. Combating Devastating COVID -19 by Drug Repurposing |pdf=|usr=}} | {{tp|p=32305589|t=ä. Combating Devastating COVID -19 by Drug Repurposing |pdf=|usr=}} | ||
{{tp|p=32325767|t=2020. COVID-19 Drug Discovery Using Intensive Approaches |pdf=|usr=}} | {{tp|p=32325767|t=2020. COVID-19 Drug Discovery Using Intensive Approaches |pdf=|usr=}} | ||
− | + | {{tp|p=32234466|t=ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives |pdf=|usr=}} | |
{{tp|p=32255648|t=ä. A Community Letter Regarding Sharing Biomolecular Simulation Data for COVID-19 |pdf=|usr=}} | {{tp|p=32255648|t=ä. A Community Letter Regarding Sharing Biomolecular Simulation Data for COVID-19 |pdf=|usr=}} | ||
{{tp|p=32315171|t=ä. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study |pdf=|usr=}} | {{tp|p=32315171|t=ä. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study |pdf=|usr=}} | ||
{{tp|p=32243270|t=2020. Potential therapeutic agents against COVID-19: What we know so far |pdf=|usr=}} | {{tp|p=32243270|t=2020. Potential therapeutic agents against COVID-19: What we know so far |pdf=|usr=}} | ||
{{tp|p=32314081|t=ä. Pharmacologic Therapy for COVID-19 Infection |pdf=|usr=}} | {{tp|p=32314081|t=ä. Pharmacologic Therapy for COVID-19 Infection |pdf=|usr=}} | ||
− | + | {{tp|p=32326602|t=2020. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 |pdf=|usr=}} | |
{{tp|p=32307245|t=ä. Treatment options for COVID-19: The reality and challenges |pdf=|usr=}} | {{tp|p=32307245|t=ä. Treatment options for COVID-19: The reality and challenges |pdf=|usr=}} | ||
{{tp|p=32251618|t=2020. Current Drugs with Potential for Treatment of COVID-19: A Literature Review |pdf=|usr=}} | {{tp|p=32251618|t=2020. Current Drugs with Potential for Treatment of COVID-19: A Literature Review |pdf=|usr=}} | ||
Zeile 50: | Zeile 50: | ||
{{tp|p=32374264|t=2020. Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point |pdf=|usr=}} | {{tp|p=32374264|t=2020. Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point |pdf=|usr=}} | ||
{{tp|p=32321634|t=2020. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome |pdf=|usr=}} | {{tp|p=32321634|t=2020. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome |pdf=|usr=}} | ||
+ | {{tp|p=32186952|t=2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics |pdf=|usr=}} | ||
+ | {{tp|p=32341599|t=2020. Is Immuno-modulation the Key to COVID-19 Pandemic?|pdf=|usr=}} | ||
+ | {{tp|p=32293807|t=2020. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID?19: initial assessment |pdf=|usr=}} | ||
+ | {{tp|p=32356252|t=ä. COVID-19: Therapeutics and Their Toxicities |pdf=|usr=}} | ||
+ | {{tp|p=32052466|t=2020. Potential interventions for novel coronavirus in China: A systematic review |pdf=|usr=}} | ||
+ | {{tp|p=32346490|t=ä. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase |pdf=|usr=}} | ||
+ | {{tp|p=32035018|t=2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option |pdf=|usr=}} | ||
+ | {{tp|p=32317113|t=2020. COVID-19 therapeutic options for patients with kidney disease |pdf=|usr=}} | ||
+ | {{tp|p=32220278|t=2020. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?|pdf=|usr=}} | ||
+ | {{tp|p=32305088|t=2020. Flooded by the torrent: the COVID-19 drug pipeline |pdf=|usr=}} | ||
+ | {{tp|p=32199468|t=ä. Use of antiviral drugs to reduce COVID-19 transmission |pdf=|usr=}} | ||
+ | {{tp|p=32325035|t=ä. Plea for multitargeted interventions for severe COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32113509|t=2020. COVID-19: combining antiviral and anti-inflammatory treatments |pdf=|usr=}} | ||
+ | {{tp|p=32368737|t=2020. Preventing COVID-19-induced pneumonia with anticytokine therapy |pdf=|usr=}} | ||
+ | {{tp|p=32278693|t=2020. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach |pdf=|usr=}} | ||
+ | {{tp|p=32198163|t=2020. Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection |pdf=|usr=}} | ||
+ | {{tp|p=32292909|t=2020. Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies |pdf=|usr=}} | ||
+ | {{tp|p=32370766|t=2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |pdf=|usr=}} | ||
+ | *[https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3 A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing] | ||
+ | {{tp|p=32231348|t=2020. Emerging prophylaxis strategies against COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32296135|t=ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?|pdf=|usr=}} | ||
+ | {{tp|p=32284951|t=2020. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options |pdf=|usr=}} | ||
+ | {{tp|p=32369479|t=2020. Antibody-based therapies for COVID-19: Can Europe move faster?|pdf=|usr=}} | ||
+ | {{tp|p=32360583|t=ä. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis |pdf=|usr=}} | ||
+ | {{tp|p=32343686|t=2020. Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks |pdf=|usr=}} | ||
+ | {{tp|p=32360480|t=ä. Candidate drugs against SARS-CoV-2 and COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32290348|t=2020. COVID-19: A Brief Overview of the Discovery Clinical Trial |pdf=|usr=}} | ||
+ | {{tp|p=32360585|t=ä. Current targeted therapeutics against COVID-19: based on first-line experience in china |pdf=|usr=}} | ||
+ | {{tp|p=32098302|t=2020. Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development |pdf=|usr=}} | ||
+ | {{tp|p=32256547|t=2020. Clinical trials on drug repositioning for COVID-19 treatment |pdf=|usr=}} | ||
+ | {{tp|p=32333199|t=ä. Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32313660|t=2020. A short review on antibody therapy for COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=C7110269|t=ä. COVID-19 Outbreak: an Update on Therapeutic Options |pdf=|usr=}} | ||
+ | {{tp|p=32124179|t=ä. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need |pdf=|usr=}} | ||
+ | {{tp|p=32334088|t=ä. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?|pdf=|usr=}} | ||
+ | {{tp|p=32278175|t=ä. COVID-19: A promising cure for the global panic |pdf=|usr=}} | ||
+ | {{tp|p=32293834|t=2020. Antiviral treatment of COVID-19|pdf=|usr=}} | ||
+ | {{tp|p=32371057|t=ä. Potential applications of plant biotechnology against SARS-CoV-2 |pdf=|usr=}} | ||
+ | {{tp|p=32291112|t=ä. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic |pdf=|usr=}} | ||
+ | {{tp|p=32287799|t=2020. Drug trials under way |pdf=|usr=}} | ||
+ | {{tp|p=32187463|t=ä. Covid-19 ? The Search for Effective Therapy |pdf=|usr=}} | ||
+ | {{tp|p=32274985|t=2020. Novel Coronavirus Disease (COVID-19): The Need for Immunoprevention at Industrial Scale |pdf=|usr=}} | ||
+ | {{tp|p=32354113|t=2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges |pdf=|usr=}} | ||
+ | {{tp|p=32326343|t=2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?|pdf=|usr=}} | ||
+ | {{tp|p=32213152|t=2020. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?|pdf=|usr=}} | ||
+ | {{ttp|p=32376392|t=ä. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions |pdf=|usr=}} | ||
+ | {{tp|p=32217607|t=2020. Covid-19: what treatments are being investigated?|pdf=|usr=}} | ||
+ | {{tp|p=32304110|t=2020. Dosing will be a key success factor in repurposing antivirals for COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32356569|t=2020. Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology |pdf=|usr=}} | ||
+ | {{tp|p=32368792|t=2020. Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2 |pdf=|usr=}} | ||
+ | {{ttp|p=32358833|t=2020. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development IUPHAR Review 29 |pdf=|usr=}} | ||
+ | {{tp|p=32329520|t=2020. Current pharmacological treatments for COVID-19: What s next?|pdf=|usr=}} | ||
+ | {{tp|p=32371479|t=2020. Cytokine Storm Drugs Move from CAR T to COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32303509|t=2020. Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19 |pdf=|usr=}} | ||
+ | |||
+ | {{ttp|p=32324951|t=2020. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics |pdf=|usr=}} | ||
+ | {{tp|p=32366720|t=2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs |pdf=|usr=}} | ||
+ | {{tp|p=32209549|t=2020. Covid-19: trials of four potential treatments to generate "robust data" of what works |pdf=|usr=}} | ||
+ | {{tp|p=32205349|t=2020. Updated Approaches against SARS-CoV-2 |pdf=|usr=}} | ||
+ | {{ttp|p=32376394|t=ä. Immunomodulatory therapy for the management of severe COVID-19 Beyond the anti-viral therapy: A comprehensive review |pdf=|usr=}} | ||
+ | {{ttp|p=32376397|t=ä. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view |pdf=|usr=}} | ||
+ | {{tp|p=32329159|t=2020. Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach |pdf=|usr=}} | ||
+ | |||
+ | {{tp|p=32345616|t=2020. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19 |pdf=|usr=}} | ||
+ | {{tp|p=32304395|t=2020. COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support |pdf=|usr=}} | ||
+ | {{tp|p=32203437|t=ä. Insights from nanomedicine into chloroquine efficacy against COVID-19 |pdf=|usr=}} | ||
+ | |||
+ | {{tp|p=32272550|t=2020. Antiviral Agents: Discovery to Resistance |pdf=|usr=}} | ||
+ | {{tp|p=32268515|t=2020. In Silico Discovery of Candidate Drugs against Covid-19 |pdf=|usr=}} | ||
+ | {{tp|p=32357553|t=2020. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19 |pdf=|usr=}} | ||
+ | |||
+ | {{tp|p=32295237|t=2020. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs |pdf=|usr=}} |
Version vom 21. Juni 2020, 11:26 Uhr
32226821 2020. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
32292689 ä. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
32318328 ä. D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19
32152082 2020. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
32232214 2020. Potential Treatments for COVID-19; a Narrative Literature Review
32134278 2020. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)
32375268 2020. Coronavirus Pandemic-Therapy and Vaccines
31996494 2020. Drug treatment options for the 2019-new coronavirus (2019-nCoV)
32334062 ä. Current status of potential therapeutic candidates for the COVID-19 crisis
32347359 ä. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19
32194980 2020. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
32149769 ä. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model
32353634 2020. COVID-19: Immunology and treatment options
32280433 ä. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
32337328 2020. Coronaviruses: A patent dataset report for research and development (R&D) analysis
32309622 ä. Emerging Therapeutic Strategies for COVID-19 patients
32336723 2020. Treatment of SARS-CoV-2: How far have we reached?
32147628 2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19)
32198066 ä. Advance of promising targets and agents against COVID-19 in China
32320852 ä. Deja vu: Stimulating open drug discovery for SARS-CoV-2
32304645 ä. Boosting the arsenal against COVID-19 through computational drug repurposing
32343658 2020. Medication for COVID-19-an Overview of Approaches Currently Under Study
32363880 2020. Medical treatment options for COVID-19
32372695 2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
32250170 2020. Will plant-made biopharmaceuticals play a role in the fight against COVID-19?
32317408 2020. Perspectives for repurposing drugs for the coronavirus disease 2019
32317405 2020. Tracking the impact of interventions against COVID-19 in absence of extensive testing
32201449 2020. Drug targets for corona virus: A systematic review
32320825 ä. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
32335561 2020. Update on treatment of COVID-19: ongoing studies between promising and disappointing results
32311668 ä. SARS-Cov-2 infection: response of human immune system and possible implications for the rapid test and treatment
32278811 ä. Drug repositioning is an alternative for the treatment of coronavirus COVID-19
32272396 ä. The Possible of Immunotherapy for COVID-19: a Systematic Review
32251732 ä. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage
32305589 ä. Combating Devastating COVID -19 by Drug Repurposing
32325767 2020. COVID-19 Drug Discovery Using Intensive Approaches
32234466 ä. Coronavirus disease 2019 (COVID-19): current status and future perspectives
32255648 ä. A Community Letter Regarding Sharing Biomolecular Simulation Data for COVID-19
32315171 ä. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study
32243270 2020. Potential therapeutic agents against COVID-19: What we know so far
32314081 ä. Pharmacologic Therapy for COVID-19 Infection
32326602 2020. Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19
32307245 ä. Treatment options for COVID-19: The reality and challenges
32251618 2020. Current Drugs with Potential for Treatment of COVID-19: A Literature Review
32361836 ä. CNS penetration of potential anti-COVID-19 drugs
32374264 2020. Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point
32321634 2020. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome
32186952 2020. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics
32341599 2020. Is Immuno-modulation the Key to COVID-19 Pandemic?
32293807 2020. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID?19: initial assessment
32356252 ä. COVID-19: Therapeutics and Their Toxicities
32052466 2020. Potential interventions for novel coronavirus in China: A systematic review
32346490 ä. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase
32035018 2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option
32317113 2020. COVID-19 therapeutic options for patients with kidney disease
32220278 2020. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
32305088 2020. Flooded by the torrent: the COVID-19 drug pipeline
32199468 ä. Use of antiviral drugs to reduce COVID-19 transmission
32325035 ä. Plea for multitargeted interventions for severe COVID-19
32113509 2020. COVID-19: combining antiviral and anti-inflammatory treatments
32368737 2020. Preventing COVID-19-induced pneumonia with anticytokine therapy
32278693 2020. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
32198163 2020. Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
32292909 2020. Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies
32370766 2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
32231348 2020. Emerging prophylaxis strategies against COVID-19
32296135 ä. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
32284951 2020. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
32369479 2020. Antibody-based therapies for COVID-19: Can Europe move faster?
32360583 ä. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis
32343686 2020. Pandemic responses: Planning to neutralize SARS-CoV-2 and prepare for future outbreaks
32360480 ä. Candidate drugs against SARS-CoV-2 and COVID-19
32290348 2020. COVID-19: A Brief Overview of the Discovery Clinical Trial
32360585 ä. Current targeted therapeutics against COVID-19: based on first-line experience in china
32098302 2020. Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development
32256547 2020. Clinical trials on drug repositioning for COVID-19 treatment
32333199 ä. Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19
32313660 2020. A short review on antibody therapy for COVID-19
C7110269 ä. COVID-19 Outbreak: an Update on Therapeutic Options
32124179 ä. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need
32334088 ä. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?
32278175 ä. COVID-19: A promising cure for the global panic
32293834 2020. Antiviral treatment of COVID-19
32371057 ä. Potential applications of plant biotechnology against SARS-CoV-2
32291112 ä. Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
32287799 2020. Drug trials under way
32187463 ä. Covid-19 ? The Search for Effective Therapy
32274985 2020. Novel Coronavirus Disease (COVID-19): The Need for Immunoprevention at Industrial Scale
32354113 2020. On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges
32326343 2020. Can Nanotechnology and Materials Science Help the Fight against SARS-CoV-2?
32213152 2020. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
32376392 ä. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions |
32217607 2020. Covid-19: what treatments are being investigated?
32304110 2020. Dosing will be a key success factor in repurposing antivirals for COVID-19
32356569 2020. Challenges in Drug Development Posed by the COVID-19 Pandemic: An Opportunity for Clinical Pharmacology
32368792 2020. Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2
32358833 2020. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development IUPHAR Review 29 |
32329520 2020. Current pharmacological treatments for COVID-19: What s next?
32371479 2020. Cytokine Storm Drugs Move from CAR T to COVID-19
32303509 2020. Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19
32324951 2020. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics |
32366720 2020. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
32209549 2020. Covid-19: trials of four potential treatments to generate "robust data" of what works
32205349 2020. Updated Approaches against SARS-CoV-2
32376394 ä. Immunomodulatory therapy for the management of severe COVID-19 Beyond the anti-viral therapy: A comprehensive review |
32376397 ä. Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view |
32329159 2020. Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach
32345616 2020. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19
32304395 2020. COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support
32203437 ä. Insights from nanomedicine into chloroquine efficacy against COVID-19
32272550 2020. Antiviral Agents: Discovery to Resistance
32268515 2020. In Silico Discovery of Candidate Drugs against Covid-19
32357553 2020. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19
32295237 2020. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs